ERCC2 and endometrial cancer: Additionally, no significant correlation was found between the ERCC2 Arg156Arg polymorphism and common gynecological tumors, including ovarian cancer, cervical cancer, and endometrial cancer (A vs C: OR 1.40, 95% CI 0.76-2.56, P= 0.278; AA + CA vs CC: OR 1.27, 95% CI 0.93-1.72, P =0.127; AA vs CA+CC: OR 1.66, 95% CI 0.57-4.82, P =0.351).